Soo Hyeon joined the lab in 2020. She received her bachelor’s degree in 2005 and Ph.D. in 2011 in the Department of Biological Sciences from KAIST (formerly the Korea Advanced Institute of Science and Technology), Republic of Korea. She was a postdoctoral fellow in the Department of Chemistry and Applied Biosciences at ETH Zurich, Switzerland. From 2017 to 2019, she was a research professor in the Department of Chemistry at KAIST. Soo Hyeon’s research interests include gene therapy using CRISPR and RNAi technology, drug formulation, and development of rare disease therapies. She is working on the development of a gene/drug delivery system for the treatment of eye diseases. She is a Mahajan Lab group leader.